Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Gauckler, P; Kesenheimer, JS; Geetha, D; Odler, B; Eller, K; Laboux, T; Alberici, F; Zappa, M; Chebotareva, N; Moiseev, S; Bonilla, M; Jhaveri, KD; Oniszczuk, J; Audard, V; Costa, D; Mastroianni-Kirsztajn, G; Bruchfeld, A; Muto, M; Windpessl, M; Mayer, G; Kronbichler, A.
COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases.
Front Immunol. 2023; 14: 1228457 Doi: 10.3389/fimmu.2023.1228457 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Eller Kathrin

Odler Balazs

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

INTRODUCTION: Patients with immune-mediated glomerular diseases are considered at high risk for severe COVID-19 outcomes. However, conclusive evidence for this patient population is scarce. METHODS: We created a global registry and retrospectively collected clinical data of patients with COVID-19 and a previously diagnosed immune-mediated glomerular disease to characterize specific risk factors for severe COVID-19 outcomes. RESULTS: Fifty-nine patients with a history of immune-mediated glomerular diseases were diagnosed with COVID-19 between 01.03.2020 and 31.08.2021. Over a mean follow-up period of 24.79 ± 18.89 days, ten patients (16.9%) developed acute kidney injury. Overall, 44.1% of patients were managed in an outpatient setting and therefore considered as having "non-severe" COVID-19, while 55.9% of patients had severe COVID-19 requiring hospitalization including worse outcomes. Comparing both groups, patients with severe COVID-19 were significantly older (53.55 ± 17.91 versus 39.77 ± 14.95 years, p = .003), had lower serum albumin levels at presentation (3.00 ± 0.80 g/dL versus 3.99 ± 0.68 g/dL, p = .016) and had a higher risk of developing acute kidney injury (27% versus 4%, p = .018). Male sex (p <.001) and ongoing intake of corticosteroids at presentation (p = .047) were also significantly associated with severe COVID-19 outcomes, while the overall use of ongoing immunosuppressive agents and glomerular disease remission status showed no significant association with the severity of COVID-19 (p = .430 and p = .326, respectively). CONCLUSION: Older age, male sex, ongoing intake of corticosteroids and lower serum albumin levels at presentation were identified as risk factors for severe COVID-19 outcomes in patients with a history of various immune-mediated glomerular diseases.

Find related publications in this database (Keywords)

coronavirus

risk factor

autoimmune disease

kidney disease

glomerulonephritis

immunosuppression

© Med Uni Graz • Imprint